Safety and Efficacy of a Low Dose Naloxone Infusion in NICU Patients

This study has been completed.
Sponsor:
Information provided by:
Children's Mercy Hospital Kansas City
ClinicalTrials.gov Identifier:
NCT00669175
First received: April 24, 2008
Last updated: July 19, 2011
Last verified: July 2011

April 24, 2008
July 19, 2011
February 2008
Not Provided
The primary outcome variable will be a change in N-PASS scores. N-PASS scores will be compared before, during, and after administration of naloxone. [ Time Frame: Before, during, and after administration of naloxone ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00669175 on ClinicalTrials.gov Archive Site
The secondary outcome variable will be any changes in dosing of opioids within four hours of initiating or increasing naloxone infusion. Vital signs will be recorded per NICU protocol and closely monitored for changes. [ Time Frame: Collected and compared for the time period before, during, and for 5 days after naloxone infusion is administered ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Safety and Efficacy of a Low Dose Naloxone Infusion in NICU Patients
Safety and Efficacy of a Low Dose Naloxone Infusion in NICU Patients

When narcotic pain medicine, like fentanyl or morphine, is given to adults and children for several days, they often develop a tolerance to the medicine. This means they may need higher doses over time to get the same amount of pain control. When it is time to stop the medicine, the dose has to be decreased slowly so that the patient does not have withdrawal symptoms.

Naloxone is a medicine that at high doses can reverse the effects of narcotics. At very small doses it may help prevent tolerance and lessen the severity of withdrawal symptoms. This could mean less narcotic pain medicine is needed over fewer days.

The purpose of this research study is to see if giving naloxone to neonates who require narcotic infusions is safe and effective. Safety will be measured by the incidence of side effects. Efficacy will be measured by monitoring for changes in pain and sedation scores and need for more pain medicine.

This is a prospective, non-randomized, single center, open label dose escalation study. We hypothesize that critically ill patients in the NICU may benefit from a low dose naloxone infusion resulting in decreased tolerance, less severe withdrawal symptoms, lower cumulative doses of opiates, and fewer total days of opiates, all while maintaining adequate or enhanced pain control and sedation. Establishing safety and efficacy data for this potentially beneficial therapy is an important first step towards using this therapy to decrease the risk of opioid tolerance and withdrawal in this population of infants.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Neonates admitted to the NICU within the first five days of life with an anticipated need for opiate infusion for at least four days

  • Opioid Tolerance
  • Pain
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
June 2011
Not Provided

Inclusion Criteria:

  • Neonates > 36 0/7 weeks estimated gestational age
  • Less than 30 days of life
  • Requiring admission to to the Neonatal Intensive Care Unit
  • Requiring continuous infusions of fentanyl or morphine analgesia
  • Anticipated to require opioid infusions for at least four days
  • Patients must be enrolled within 120 hours of initiating opioid infusions
  • All patients will also require mechanical ventilation prior to study entry.

Exclusion Criteria:

  • Preterm infants < 36 weeks gestation
  • Neonates with major neurologic anomalies, seizures
  • Opioid infusion administration for > 120 hours prior to study entry
  • Patients requiring ECMO support prior to study entry
  • Neonates born to mothers who are known to be opioid dependent
Both
up to 30 Days
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00669175
08 01-003
No
Eugenia Pallotto, Children's Mercy Hospital
Children's Mercy Hospital Kansas City
Not Provided
Principal Investigator: Eugenia K Pallotto, MD Children's Mercy Hospital
Children's Mercy Hospital Kansas City
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP